Co-Diagnostics's Total Assets for the quarter that ended in Dec. 2023 was $95.32 Mil.
During the past 12 months, Co-Diagnostics's average Total Assets Growth Rate was -12.10% per year.
During the past 3 years, the average Total Assets Growth Rate was 15.40% per year.
During the past 5 years, the average Total Assets Growth Rate was 149.40% per year.
During the past 9 years, Co-Diagnostics's highest 3-Year average Total Assets Growth Rate was 388.20%. The lowest was 15.40%. And the median was 120.65%.
The historical data trend for Co-Diagnostics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Co-Diagnostics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Co-Diagnostics (NAS:CODX) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Co-Diagnostics's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Co-Diagnostics Total Assets Related Terms
Thank you for viewing the detailed overview of Co-Diagnostics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Co-Diagnostics (Co-Diagnostics) Business Description
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV. The company's diagnostics systems enable very rapid, low-cost, sophisticated molecular testing for organisms and genetic diseases by greatly automating historically complex procedures in both the development and administration of tests.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CODX has been successfully added to your 